Melanotan I (Afamelanotide, [Nle4, D-Phe7]-α-MSH) is a linear 13-amino acid α-MSH analogue demonstrating high selectivity for MC1R melanogenesis and photoprotective signaling without significant central MC4R activity.
Scientific Profile & Research Key Points: Melanotan I
Melanotan I (Afamelanotide, [Nle4, D-Phe7]-α-MSH) is a linear 13-amino acid α-MSH analogue demonstrating high selectivity for MC1R melanogenesis and photoprotective signaling without significant central MC4R activity.
Active Batch Release Specifications (Lot SL-2026-144)
Analytical release verification for current Melanotan I (10 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-144 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water (1.0–2.0 mL)
Temperature & Stability
Store lyophilized at -20°C shielded from light; refrigerate solution at 2°C–8°C for up to 28 days.
Melanotan I — Technical Questions & Answers
What is the molar concentration when reconstituting Melanotan I (10 mg) in 2.0 mL?
Reconstituting the full 10 mg vial of Melanotan I (MW 1646.85 g/mol) in 2.0 mL of diluent produces a 5.00 mg/mL stock solution — equivalent to approximately 3.04 mM (3,036 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does Melanotan I's counterion stoichiometry affect assay mass calculations?
Melanotan I (CAS 75921-69-6, formula C78H111N21O19) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify Melanotan I Lot SL-2026-144 and what pathway does it target?
Lot SL-2026-144 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 1646.85 g/mol. In preclinical literature, Melanotan I targets Selective Melanocortin-1 Receptor (MC1R) Agonist (Sawyer T.K. et al., Proc Natl Acad Sci USA (1980) — [Nle4, D-Phe7]-α-MSH superpotent MC1R analogue (PMID: 6777774)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
Melanotan II: Cyclic Lactam Architecture, Melanocortin Receptor Subtypes, and Potency
A structural review of cyclic heptapeptide Melanotan II (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2). Receptor affinities (MC1R–MC5R), cyclic lactam stability, and analytical standards.
How to Read a Peptide Certificate of Analysis (COA): Step-by-Step Breakdown
A practical guide for researchers. How to analyze HPLC chromatograms, verify retention time, interpret mass spec m/z peaks, evaluate counterion salt ratios, and spot fraudulent documents.
How to Reconstitute Research Peptides: Complete Laboratory Protocol and Best Practices
Standard Operating Procedure (SOP) for peptide reconstitution. Diluent selection (BAC water vs acetic acid), meniscus calculations, avoiding foaming, and cold storage parameters.